Skyrizi (Risankizumab) Shortage Update: What Patients Need to Know in 2026

Many patients searching for Skyrizi (risankizumab-rzaa) wonder if there is a shortage in 2026. The short answer: No, Skyrizi is not on the FDA Drug Shortage list. But that doesn't mean getting it is easy. Patients across the country continue to face significant barriers — not because the drug isn't being made, but because the access system for specialty biologics is complex and often frustrating to navigate.

This 2026 update covers the current availability status, the real reasons patients struggle to get Skyrizi, and what you can do to speed up access.

Current Skyrizi Availability Status (2026)

As of 2026, Skyrizi is commercially available in all FDA-approved formulations:

150 mg/mL prefilled autoinjector pen and syringe (for psoriasis and PsA)

600 mg/10 mL vial for IV infusion (for Crohn's and UC induction)

180 mg and 360 mg prefilled cartridges with on-body injector (for Crohn's and UC maintenance)

AbbVie has reported continued strong growth for Skyrizi, and no manufacturing or distribution disruptions have been announced. Biosimilar competition is not expected until after 2028.

So Why Can't Patients Get It? The Real Access Barriers

The barriers to Skyrizi access are administrative, not supply-based. Here are the most common reasons patients face delays or denials:

1. Prior Authorization Delays (7–45 Days)

Virtually every insurer requires prior authorization before covering Skyrizi. The PA process involves submitting clinical documentation of your diagnosis, treatment history, and why Skyrizi is necessary. Approval times range from 7 to 45 days. Initial denials are common, requiring appeals that add more time.

2. Step Therapy Requirements

Most insurance plans require patients to try and fail at least one TNF inhibitor (like adalimumab or infliximab) before approving Skyrizi. If you haven't failed a step therapy requirement yet, your insurer may force you through that process first — which can delay access by months.

3. Specialty-Pharmacy-Only Distribution

Skyrizi cannot be dispensed at standard retail pharmacies. It is only available through specialty pharmacy networks. Finding an in-network specialty pharmacy that can fill the prescription and has availability in your area can be a challenge — especially in rural regions.

4. PA Renewal Requirements Every 6–12 Months

Even after you've been on Skyrizi for a year or more, your insurer typically requires PA renewal every 6 to 12 months. A lapsed PA can suddenly block your next dose — even after years of successful treatment. Staying on top of renewal deadlines is critical.

What Patients Can Do Right Now

Enroll in Skyrizi Complete. Call 1-866-SKYRIZI to get a patient support nurse and case manager assigned to you. They can help navigate PA, appeals, and pharmacy coordination.

Ask for expedited PA review. If your doctor documents urgent medical need, many insurers must respond within 72 hours rather than the standard 7–45 days.

Use medfinder to find available pharmacies. Once your PA is approved, medfinder can call specialty pharmacies near you to identify which ones can fill your prescription — saving you hours of hold time.

Consider a bridge program. If your PA is denied, AbbVie's bridge program through Skyrizi Complete can provide medication at no charge for up to 2 years while you appeal, for eligible commercially insured patients.

Looking Ahead: Will Access Get Easier?

Access to Skyrizi is unlikely to become dramatically easier in the near term. The administrative PA and step therapy barriers are embedded in insurance plan design. However, as Skyrizi gains more market share and prescribers become more skilled at navigating PA, approval rates should improve over time.

Biosimilar competition after 2028 may eventually reduce costs and some access barriers — but that's still several years away.

For step-by-step help, see How to Find Skyrizi In Stock Near You, or use medfinder to start your search today.